Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile X syndrome.
Jordan E Norris, Elizabeth M Berry-Kravis, Mark D Harnett and 7 others
PMID 39488698WHAT IT FOUND
Higher blood levels of BPN14770 correlated with reduced auditory brain responses in 12 men with fragile X syndrome.
This supports the drug's biological action on neural hyperexcitability but does not prove clinical efficacy. The effect was not seen when measuring change from baseline.
Key findings
01In participants who received BPN14770 during period 1, serum drug concentration showed a significant positive correlation with absolute N1 amplitude, indicating a reduction in this negative-going neural response.
02When N1 amplitude was measured as a change from baseline rather than an absolute value, the relationship with serum drug concentration was not statistically significant.
03The analysis relied on a very small subset of 12 valid participants for the drug-only correlation, limiting the certainty of the finding.
STILL TO COME
How it was doneWhat they foundWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The sample size for the key correlation was very small (12 participants), which reduces statistical power and increases the risk of false positives. The study lacked a sufficient washout period, so the analysis had to rely on cross-sectional data at the crossover point rather than a clean within-subject comparison. Data loss due to movement artifacts and EEG noise further reduced the number of usable participants. The relationship between drug levels and brain activity was not significant when measured as a change from baseline, only when using absolute values. Cyclic AMP (cAMP) levels, the direct biological target of the drug, were not measured, so target engagement could not be confirmed independently of the EEG marker.
Declared interests
The study was funded by the FRAXA Research Foundation, the National Institutes of Health, and Tetra Therapeutics, the company developing the drug.
The easy way to misread this
Do not interpret the significant correlation between drug levels and N1 amplitude as proof that BPN14770 improves clinical symptoms. The finding is based on a very small subgroup (12 people), disappears when measuring change from baseline, and reflects a physiological marker rather than a functional outcome.